

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

Srivichaivejvivat Public Company Limited  
and its subsidiaries  
Review report and consolidated and separate financial  
information  
For the three-month and six-month periods ended  
30 June 2026

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

## **Independent Auditor's Report on Review of Interim Financial Information**

To the Shareholders of Srivichaivejvivat Public Company Limited

I have reviewed the accompanying consolidated financial information of Srivichaivejvivat Public Company Limited and its subsidiaries, which comprises the consolidated statements of financial position as at 30 June 2026, the related consolidated statements of comprehensive income for the three-month and six-month periods then ended, the related consolidated statements of changes in shareholders' equity and cash flows for the six-month period then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Srivichaivejvivat Public Company Limited for the same periods (collectively "the interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*. My responsibility is to express a conclusion on this interim financial information based on my review.

### **Scope of Review**

I conducted my review in accordance with Thai Standard on Review Engagements 2410, *Review of Interim Financial Information Performed by the Independent Auditor of the Entity*. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards as applicable to auditing issued by the Federation of Accounting Professions and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

### **Conclusion**

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 *Interim Financial Reporting*.

Termphong Opanaphan

Certified Public Accountant (Thailand) No. 4501

EY Office Limited

Bangkok: 14 August 2026

**Srivichaivejvivat Public Company Limited and its subsidiaries**

**Statements of financial position**

**As at 30 June 2026**

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht)

|                                           |      | Consolidated financial statements |                  | Separate financial statements |                  |
|-------------------------------------------|------|-----------------------------------|------------------|-------------------------------|------------------|
|                                           | Note | 30 June 2026                      | 31 December 2025 | 30 June 2026                  | 31 December 2025 |
|                                           |      | (Unaudited<br>but reviewed)       | (Audited)        | (Unaudited<br>but reviewed)   | (Audited)        |
| Assets                                    |      |                                   |                  |                               |                  |
| Current assets                            |      |                                   |                  |                               |                  |
| Cash and cash equivalents                 |      | 733,905                           | 807,291          | 227,458                       | 227,553          |
| Trade and other current receivables       | 3    | 634,326                           | 635,142          | 230,540                       | 234,613          |
| Current portion of lease receivables      |      | -                                 | -                | 384                           | 375              |
| Medicine and supplies                     |      | 73,310                            | 57,492           | 22,729                        | 19,162           |
| Other current financial assets            |      | 682,579                           | 570,127          | 445,737                       | 333,646          |
| Other current assets                      |      | 12,673                            | 9,894            | 4,396                         | 3,299            |
| Total current assets                      |      | 2,136,793                         | 2,079,946        | 931,244                       | 818,648          |
| Non-current assets                        |      |                                   |                  |                               |                  |
| Restricted bank deposits                  |      | 410                               | 410              | -                             | -                |
| Lease receivables, net of current portion |      | -                                 | -                | 9,857                         | 10,051           |
| Other non-current financial assets        |      | 52,488                            | 52,488           | 52,488                        | 52,488           |
| Investments in subsidiaries               |      | -                                 | -                | 1,058,433                     | 1,058,433        |
| Investment properties                     |      | -                                 | -                | 33,095                        | 33,095           |
| Property, plant and equipment             |      | 2,226,912                         | 2,264,515        | 1,086,963                     | 1,107,615        |
| Right-of-use assets                       |      | 33,377                            | 34,578           | -                             | -                |
| Deferred tax assets                       |      | 21,991                            | 19,963           | -                             | -                |
| Other non-current assets                  |      | 19,333                            | 24,611           | 11,590                        | 14,109           |
| Total non-current assets                  |      | 2,354,511                         | 2,396,565        | 2,252,426                     | 2,275,791        |
| Total assets                              |      | 4,491,304                         | 4,476,511        | 3,183,670                     | 3,094,439        |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

**Srivichaivejvivat Public Company Limited and its subsidiaries**

**Statements of financial position (continued)**

**As at 30 June 2026**

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht)

|                                             | <b>Consolidated financial statements</b> |                         | <b>Separate financial statements</b> |                         |
|---------------------------------------------|------------------------------------------|-------------------------|--------------------------------------|-------------------------|
|                                             | <u>30 June 2026</u>                      | <u>31 December 2025</u> | <u>30 June 2026</u>                  | <u>31 December 2025</u> |
|                                             | (Unaudited<br>but reviewed)              | (Audited)               | (Unaudited<br>but reviewed)          | (Audited)               |
| <b>Liabilities and shareholders' equity</b> |                                          |                         |                                      |                         |
| <b>Current liabilities</b>                  |                                          |                         |                                      |                         |
| Trade and other current payables            | 382,360                                  | 392,380                 | 173,651                              | 175,670                 |
| Current portion of lease liabilities        | 9,438                                    | 9,085                   | -                                    | -                       |
| Income tax payable                          | 35,772                                   | 41,973                  | 14,997                               | 15,484                  |
| Other current liabilities                   | 5,234                                    | 4,623                   | 1,474                                | 1,525                   |
| <b>Total current liabilities</b>            | <b>432,804</b>                           | <b>448,061</b>          | <b>190,122</b>                       | <b>192,679</b>          |
| <b>Non-current liabilities</b>              |                                          |                         |                                      |                         |
| Lease liabilities, net of current portion   | 56,194                                   | 58,388                  | -                                    | -                       |
| Non-current provision for employee benefits | 94,140                                   | 89,772                  | 27,064                               | 25,706                  |
| Deferred tax liabilities                    | 247                                      | 638                     | 220                                  | 607                     |
| <b>Total non-current liabilities</b>        | <b>150,581</b>                           | <b>148,798</b>          | <b>27,284</b>                        | <b>26,313</b>           |
| <b>Total liabilities</b>                    | <b>583,385</b>                           | <b>596,859</b>          | <b>217,406</b>                       | <b>218,992</b>          |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

**Srivichaivejvivat Public Company Limited and its subsidiaries**

**Statements of financial position (continued)**

**As at 30 June 2026**

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht)

|                                                                   | Note | Consolidated financial statements |                  | Separate financial statements |                  |
|-------------------------------------------------------------------|------|-----------------------------------|------------------|-------------------------------|------------------|
|                                                                   |      | 30 June 2026                      | 31 December 2025 | 30 June 2026                  | 31 December 2025 |
|                                                                   |      | (Unaudited<br>but reviewed)       | (Audited)        | (Unaudited<br>but reviewed)   | (Audited)        |
| <b>Shareholders' equity</b>                                       |      |                                   |                  |                               |                  |
| Share capital                                                     | 4    |                                   |                  |                               |                  |
| Registered                                                        |      |                                   |                  |                               |                  |
| 627,731,979 ordinary shares of Baht 1 each                        |      | 627,732                           | 627,732          | 627,732                       | 627,732          |
| Issued and fully paid                                             |      |                                   |                  |                               |                  |
| 618,646,723 ordinary shares of Baht 1 each                        |      |                                   |                  |                               |                  |
| (31 December 2025: 608,774,132<br>ordinary shares of Baht 1 each) |      | 618,647                           | 608,774          | 618,647                       | 608,774          |
| Share premium                                                     | 4    | 372,484                           | 303,376          | 372,484                       | 303,376          |
| Treasury shares                                                   | 5    | (2,787)                           | (2,787)          | (2,787)                       | (2,787)          |
| Advance received from share subscription                          | 4    | 68,656                            | 78,981           | 68,656                        | 78,981           |
| Retained earnings                                                 |      |                                   |                  |                               |                  |
| Appropriated - statutory reserve                                  |      | 62,773                            | 62,773           | 62,773                        | 62,773           |
| Appropriated - treasury share reserve                             | 5    | 2,787                             | 2,787            | 2,787                         | 2,787            |
| Unappropriated                                                    |      | 2,752,002                         | 2,792,052        | 1,834,114                     | 1,811,953        |
| Other components of shareholders' equity                          |      | 28,260                            | 28,260           | 9,590                         | 9,590            |
| Equity attributable to owners of the Company                      |      | 3,902,822                         | 3,874,216        | 2,966,264                     | 2,875,447        |
| Non-controlling interests of the subsidiaries                     |      | 5,097                             | 5,436            | -                             | -                |
| <b>Total shareholders' equity</b>                                 |      | <b>3,907,919</b>                  | <b>3,879,652</b> | <b>2,966,264</b>              | <b>2,875,447</b> |
| <b>Total liabilities and shareholders' equity</b>                 |      | <b>4,491,304</b>                  | <b>4,476,511</b> | <b>3,183,670</b>              | <b>3,094,439</b> |

The accompanying notes are an integral part of the financial statements.

Directors

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

**Srivichaivejvivat Public Company Limited and its subsidiaries****Statements of comprehensive income****For the three-month period ended 30 June 2026****DRAFT***This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht, except earnings per share expressed in Baht)

|                                                      |      | Consolidated financial statements |                | Separate financial statements |                |
|------------------------------------------------------|------|-----------------------------------|----------------|-------------------------------|----------------|
|                                                      | Note | 2026                              | 2025           | 2026                          | 2025           |
| <b>Profit or loss:</b>                               |      |                                   |                |                               |                |
| <b>Revenues</b>                                      |      |                                   |                |                               |                |
| Revenues from hospital operations                    |      | 753,193                           | 725,238        | 302,465                       | 281,933        |
| Dividend income                                      |      | 2,835                             | 4,050          | 181,602                       | 168,731        |
| Other income                                         |      | 10,651                            | 9,184          | 3,783                         | 3,196          |
| <b>Total revenues</b>                                |      | <u>766,679</u>                    | <u>738,472</u> | <u>487,850</u>                | <u>453,860</u> |
| <b>Expenses</b>                                      |      |                                   |                |                               |                |
| Cost of hospital operations                          |      | 546,286                           | 535,704        | 208,367                       | 202,444        |
| Selling expenses                                     |      | 12,731                            | 18,200         | 5,240                         | 5,380          |
| Administrative expenses                              |      | 72,053                            | 63,292         | 28,315                        | 26,616         |
| <b>Total expenses</b>                                |      | <u>631,070</u>                    | <u>617,196</u> | <u>241,922</u>                | <u>234,440</u> |
| <b>Operating profit</b>                              |      | <u>135,609</u>                    | <u>121,276</u> | <u>245,928</u>                | <u>219,420</u> |
| Finance cost                                         |      | (1,021)                           | (1,008)        | -                             | -              |
| <b>Profit before income tax expenses</b>             |      | <u>134,588</u>                    | <u>120,268</u> | <u>245,928</u>                | <u>219,420</u> |
| Income tax expenses                                  |      | (26,246)                          | (23,197)       | (12,834)                      | (10,102)       |
| <b>Profit for the period</b>                         |      | <u>108,342</u>                    | <u>97,071</u>  | <u>233,094</u>                | <u>209,318</u> |
| <b>Other comprehensive income for the period</b>     |      | -                                 | -              | -                             | -              |
| <b>Total comprehensive income for the period</b>     |      | <u>108,342</u>                    | <u>97,071</u>  | <u>233,094</u>                | <u>209,318</u> |
| <b>Profit attributable to:</b>                       |      |                                   |                |                               |                |
| Equity holders of the Company                        |      | 108,099                           | 96,815         | <u>233,094</u>                | <u>209,318</u> |
| Non-controlling interests of the subsidiaries        |      | 243                               | 256            |                               |                |
|                                                      |      | <u>108,342</u>                    | <u>97,071</u>  |                               |                |
| <b>Total comprehensive income attributable to:</b>   |      |                                   |                |                               |                |
| Equity holders of the Company                        |      | 108,099                           | 96,815         | <u>233,094</u>                | <u>209,318</u> |
| Non-controlling interests of the subsidiaries        |      | 243                               | 256            |                               |                |
|                                                      |      | <u>108,342</u>                    | <u>97,071</u>  |                               |                |
| <b>Earnings per share (Baht)</b>                     | 6    |                                   |                |                               |                |
| Basic earnings per share                             |      |                                   |                |                               |                |
| Profit attributable to equity holders of the Company |      | 0.1748                            | 0.1591         | 0.3770                        | 0.3440         |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

(Unaudited but reviewed)

**Srivichaivejvivat Public Company Limited and its subsidiaries****Statements of comprehensive income****For the six-month period ended 30 June 2026****DRAFT***This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht, except earnings per share expressed in Baht)

|                                                      |      | Consolidated financial statements |           | Separate financial statements |          |
|------------------------------------------------------|------|-----------------------------------|-----------|-------------------------------|----------|
|                                                      | Note | 2026                              | 2025      | 2026                          | 2025     |
| Profit or loss:                                      |      |                                   |           |                               |          |
| Revenues                                             |      |                                   |           |                               |          |
| Revenues from hospital operations                    |      | 1,491,076                         | 1,425,284 | 582,056                       | 556,948  |
| Dividend income                                      |      | 2,835                             | 4,050     | 181,602                       | 367,706  |
| Other income                                         |      | 16,925                            | 20,241    | 6,715                         | 8,100    |
| Total revenues                                       |      | 1,510,836                         | 1,449,575 | 770,373                       | 932,754  |
| Expenses                                             |      |                                   |           |                               |          |
| Cost of hospital operations                          |      | 1,080,104                         | 1,046,556 | 411,030                       | 403,131  |
| Selling expenses                                     |      | 29,647                            | 38,920    | 11,400                        | 11,475   |
| Administrative expenses                              |      | 140,034                           | 120,859   | 56,590                        | 45,034   |
| Total expenses                                       |      | 1,249,785                         | 1,206,335 | 479,020                       | 459,640  |
| Operating profit                                     |      | 261,051                           | 243,240   | 291,353                       | 473,114  |
| Finance cost                                         |      | (2,053)                           | (2,385)   | -                             | (339)    |
| Profit before income tax expenses                    |      | 258,998                           | 240,855   | 291,353                       | 472,775  |
| Income tax expenses                                  |      | (51,196)                          | (44,938)  | (21,895)                      | (18,680) |
| Profit for the period                                |      | 207,802                           | 195,917   | 269,458                       | 454,095  |
| Other comprehensive income for the period            |      |                                   |           |                               |          |
|                                                      |      | -                                 | -         | -                             | -        |
| Total comprehensive income for the period            |      | 207,802                           | 195,917   | 269,458                       | 454,095  |
| Profit attributable to:                              |      |                                   |           |                               |          |
| Equity holders of the Company                        |      | 207,247                           | 195,401   | 269,458                       | 454,095  |
| Non-controlling interests of the subsidiaries        |      | 555                               | 516       |                               |          |
|                                                      |      | 207,802                           | 195,917   |                               |          |
| Total comprehensive income attributable to:          |      |                                   |           |                               |          |
| Equity holders of the Company                        |      | 207,247                           | 195,401   | 269,458                       | 454,095  |
| Non-controlling interests of the subsidiaries        |      | 555                               | 516       |                               |          |
|                                                      |      | 207,802                           | 195,917   |                               |          |
| Earnings per share (Baht)                            |      |                                   |           |                               |          |
| 6                                                    |      |                                   |           |                               |          |
| Basic earnings per share                             |      |                                   |           |                               |          |
| Profit attributable to equity holders of the Company |      | 0.3355                            | 0.3210    | 0.4362                        | 0.7461   |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity

For the six-month period ended 30 June 2026

**DRAFT**  
This document is a draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

| Consolidated financial statements                                |                                              |               |                 |                                          |                                  |                                       |                |                                                                     |                                                                                 |                                                       |                               |                                                    |                                                                      |                            |
|------------------------------------------------------------------|----------------------------------------------|---------------|-----------------|------------------------------------------|----------------------------------|---------------------------------------|----------------|---------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------|-------------------------------|----------------------------------------------------|----------------------------------------------------------------------|----------------------------|
| Equity attributable to owners of the Company                     |                                              |               |                 |                                          |                                  |                                       |                |                                                                     |                                                                                 |                                                       |                               |                                                    |                                                                      |                            |
|                                                                  | Equity attributable to owners of the Company |               |                 |                                          |                                  |                                       |                | Other components of shareholders' equity                            |                                                                                 |                                                       |                               |                                                    |                                                                      |                            |
|                                                                  |                                              |               |                 |                                          |                                  |                                       |                | Other changes by the owners                                         |                                                                                 |                                                       | Other comprehensive           |                                                    |                                                                      |                            |
|                                                                  |                                              |               |                 |                                          |                                  |                                       |                | Difference resulting from business combination under common control | Change in parent's ownership interest in subsidiaries without change in control | Gain on investment in equity designated at fair value | Total of shareholders' equity | Total equity attributable to owners of the Company | Equity attributable to non-controlling interests of the subsidiaries | Total shareholders' equity |
|                                                                  | Issued and paid-up share capital             | Share premium | Treasury shares | Advance received from share subscription | Appropriated - statutory reserve | Appropriated - treasury share reserve | Unappropriated |                                                                     |                                                                                 |                                                       |                               |                                                    |                                                                      |                            |
| Balance as at 1 January 2025                                     | 608,709                                      | 302,926       | -               | 515                                      | 62,773                           | -                                     | 2,510,847      | 37,531                                                              | (18,861)                                                                        | 9,461                                                 | 28,131                        | 3,513,901                                          | 5,996                                                                | 3,519,897                  |
| Profit for the period                                            | -                                            | -             | -               | -                                        | -                                | -                                     | 195,401        | -                                                                   | -                                                                               | -                                                     | -                             | 195,401                                            | 516                                                                  | 195,917                    |
| Other comprehensive income for the period                        | -                                            | -             | -               | -                                        | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | -                                                  | -                                                                    | -                          |
| Total comprehensive income for the period                        | -                                            | -             | -               | -                                        | -                                | -                                     | 195,401        | -                                                                   | -                                                                               | -                                                     | -                             | 195,401                                            | 516                                                                  | 195,917                    |
| Issue ordinary shares as a result of warrants exercised (Note 4) | 65                                           | 450           | -               | (515)                                    | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | -                                                  | -                                                                    | -                          |
| Treasury shares (Note 5)                                         | -                                            | -             | (2,787)         | -                                        | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | (2,787)                                            | -                                                                    | (2,787)                    |
| Treasury share reserve (Note 5)                                  | -                                            | -             | -               | -                                        | -                                | 2,787                                 | (2,787)        | -                                                                   | -                                                                               | -                                                     | -                             | -                                                  | -                                                                    | -                          |
| Dividend paid (Note 8)                                           | -                                            | -             | -               | -                                        | -                                | -                                     | (152,194)      | -                                                                   | -                                                                               | -                                                     | -                             | (152,194)                                          | (1,811)                                                              | (154,005)                  |
| Balance as at 30 June 2025                                       | 608,774                                      | 303,376       | (2,787)         | -                                        | 62,773                           | 2,787                                 | 2,551,267      | 37,531                                                              | (18,861)                                                                        | 9,461                                                 | 28,131                        | 3,554,321                                          | 4,701                                                                | 3,559,022                  |
| Balance as at 1 January 2026                                     | 608,774                                      | 303,376       | (2,787)         | 78,981                                   | 62,773                           | 2,787                                 | 2,792,052      | 37,531                                                              | (18,861)                                                                        | 9,590                                                 | 28,260                        | 3,874,216                                          | 5,436                                                                | 3,879,652                  |
| Profit for the period                                            | -                                            | -             | -               | -                                        | -                                | -                                     | 207,247        | -                                                                   | -                                                                               | -                                                     | -                             | 207,247                                            | 555                                                                  | 207,802                    |
| Other comprehensive income for the period                        | -                                            | -             | -               | -                                        | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | -                                                  | -                                                                    | -                          |
| Total comprehensive income for the period                        | -                                            | -             | -               | -                                        | -                                | -                                     | 207,247        | -                                                                   | -                                                                               | -                                                     | -                             | 207,247                                            | 555                                                                  | 207,802                    |
| Issue ordinary shares as a result of warrants exercised (Note 4) | 9,873                                        | 69,108        | -               | (78,981)                                 | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | -                                                  | -                                                                    | -                          |
| Advance received from share subscription (Note 4)                | -                                            | -             | -               | 68,656                                   | -                                | -                                     | -              | -                                                                   | -                                                                               | -                                                     | -                             | 68,656                                             | -                                                                    | 68,656                     |
| Dividend paid (Note 8)                                           | -                                            | -             | -               | -                                        | -                                | -                                     | (247,297)      | -                                                                   | -                                                                               | -                                                     | -                             | (247,297)                                          | (894)                                                                | (248,191)                  |
| Balance as at 30 June 2026                                       | 618,647                                      | 372,484       | (2,787)         | 68,656                                   | 62,773                           | 2,787                                 | 2,752,002      | 37,531                                                              | (18,861)                                                                        | 9,590                                                 | 28,260                        | 3,902,822                                          | 5,097                                                                | 3,907,919                  |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

(Unaudited but reviewed)

Srivichaivejvivat Public Company Limited and its subsidiaries

Statements of changes in shareholders' equity (continued)

For the six-month period ended 30 June 2026

**DRAFT**

This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.

(Unit: Thousand Baht)

## Separate financial statements

|                                                                  |                |                |                 |                  |                   |                        |                  | Other components        | Total                |
|------------------------------------------------------------------|----------------|----------------|-----------------|------------------|-------------------|------------------------|------------------|-------------------------|----------------------|
|                                                                  |                |                |                 |                  |                   |                        |                  | of shareholders' equity |                      |
|                                                                  |                |                |                 |                  |                   |                        |                  | Other comprehensive     |                      |
|                                                                  |                |                |                 |                  |                   |                        |                  | income                  |                      |
|                                                                  | Issued and     | Share premium  | Treasury shares | Advance received | Retained earnings |                        |                  | Gain on investment      | Total                |
|                                                                  | paid-up        |                |                 | from share       | Appropriated -    | Appropriated -         |                  | in equity designated    |                      |
|                                                                  | share capital  |                |                 | subscription     | statutory reserve | treasury share reserve | Unappropriated   | at fair value           | shareholders' equity |
| <b>Balance as at 1 January 2025</b>                              | 608,709        | 302,926        | -               | 515              | 62,773            | -                      | 1,420,677        | 9,461                   | 2,405,061            |
| Profit for the period                                            | -              | -              | -               | -                | -                 | -                      | 454,095          | -                       | 454,095              |
| Other comprehensive income for the period                        | -              | -              | -               | -                | -                 | -                      | -                | -                       | -                    |
| Total comprehensive income for the period                        | -              | -              | -               | -                | -                 | -                      | 454,095          | -                       | 454,095              |
| Issue ordinary shares as a result of warrants exercised (Note 4) | 65             | 450            | -               | (515)            | -                 | -                      | -                | -                       | -                    |
| Treasury shares (Note 5)                                         | -              | -              | (2,787)         | -                | -                 | -                      | -                | -                       | (2,787)              |
| Treasury share reserve (Note 5)                                  | -              | -              | -               | -                | -                 | 2,787                  | (2,787)          | -                       | -                    |
| Dividend paid (Note 8)                                           | -              | -              | -               | -                | -                 | -                      | (152,194)        | -                       | (152,194)            |
| <b>Balance as at 30 June 2025</b>                                | <u>608,774</u> | <u>303,376</u> | <u>(2,787)</u>  | <u>-</u>         | <u>62,773</u>     | <u>2,787</u>           | <u>1,719,791</u> | <u>9,461</u>            | <u>2,704,175</u>     |
| <b>Balance as at 1 January 2026</b>                              | 608,774        | 303,376        | (2,787)         | 78,981           | 62,773            | 2,787                  | 1,811,953        | 9,590                   | 2,875,447            |
| Profit for the period                                            | -              | -              | -               | -                | -                 | -                      | 269,458          | -                       | 269,458              |
| Other comprehensive income for the period                        | -              | -              | -               | -                | -                 | -                      | -                | -                       | -                    |
| Total comprehensive income for the period                        | -              | -              | -               | -                | -                 | -                      | 269,458          | -                       | 269,458              |
| Issue ordinary shares as a result of warrants exercised (Note 4) | 9,873          | 69,108         | -               | (78,981)         | -                 | -                      | -                | -                       | -                    |
| Advance received from share subscription (Note 4)                | -              | -              | -               | 68,656           | -                 | -                      | -                | -                       | 68,656               |
| Dividend paid (Note 8)                                           | -              | -              | -               | -                | -                 | -                      | (247,297)        | -                       | (247,297)            |
| <b>Balance as at 30 June 2026</b>                                | <u>618,647</u> | <u>372,484</u> | <u>(2,787)</u>  | <u>68,656</u>    | <u>62,773</u>     | <u>2,787</u>           | <u>1,834,114</u> | <u>9,590</u>            | <u>2,966,264</u>     |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

The accompanying notes are an integral part of the financial statements.

(Unaudited but reviewed)

**Srivichaivejvivat Public Company Limited and its subsidiaries****Cash flow statements****For the six-month period ended 30 June 2026****DRAFT***This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht)

|                                                                                                      | <b>Consolidated financial statements</b> |                | <b>Separate financial statements</b> |                |
|------------------------------------------------------------------------------------------------------|------------------------------------------|----------------|--------------------------------------|----------------|
|                                                                                                      | <u>2026</u>                              | <u>2025</u>    | <u>2026</u>                          | <u>2025</u>    |
| <b>Cash flows from operating activities</b>                                                          |                                          |                |                                      |                |
| Profit before tax                                                                                    | 258,998                                  | 240,855        | 291,353                              | 472,775        |
| Adjustments to reconcile profit before tax to net cash provided by (paid from) operating activities: |                                          |                |                                      |                |
| Depreciation and amortisation                                                                        | 95,401                                   | 90,702         | 44,791                               | 42,413         |
| Allowance for expected credit losses (reversal)                                                      | 7,106                                    | 845            | 184                                  | (236)          |
| Loss on write-off of bad debt                                                                        | -                                        | 401            | -                                    | 401            |
| Reduction of medicine and supplies to net realisable value                                           | 155                                      | 341            | 58                                   | 90             |
| Gain on disposals of equipment                                                                       | (148)                                    | (56)           | (21)                                 | (113)          |
| Loss on write-off of equipment                                                                       | 531                                      | 107            | 75                                   | 14             |
| Non-current provision for employee benefits                                                          | 4,368                                    | 4,285          | 1,358                                | 1,307          |
| Dividend income                                                                                      | (2,835)                                  | (4,050)        | (181,602)                            | (367,706)      |
| Interest income                                                                                      | (5,926)                                  | (7,867)        | (3,228)                              | (1,942)        |
| Finance cost                                                                                         | 2,053                                    | 2,385          | -                                    | 339            |
| Profit from operating activities before changes in operating assets and liabilities                  | 359,703                                  | 327,948        | 152,968                              | 147,342        |
| Operating assets (increase) decrease                                                                 |                                          |                |                                      |                |
| Trade and other current receivables                                                                  | (4,438)                                  | (9,348)        | 4,697                                | 7,503          |
| Medicine and supplies                                                                                | (15,973)                                 | 1,326          | (3,625)                              | 82             |
| Other current assets                                                                                 | (2,779)                                  | (596)          | (1,097)                              | 1,018          |
| Other non-current assets                                                                             | 2,509                                    | (2,200)        | 296                                  | (595)          |
| Operating liabilities increase (decrease)                                                            |                                          |                |                                      |                |
| Trade and other current payables                                                                     | 3,795                                    | (4,858)        | (3,953)                              | (16,699)       |
| Other current liabilities                                                                            | 611                                      | (12,427)       | (51)                                 | (13,000)       |
| Cash flows from operating activities                                                                 | 343,428                                  | 299,845        | 149,235                              | 125,651        |
| Interest received                                                                                    | 2,275                                    | 5,062          | 491                                  | 990            |
| Cash paid for corporate income tax and withholding tax deducted at source                            | (59,816)                                 | (42,229)       | (22,769)                             | (13,205)       |
| <b>Net cash from operating activities</b>                                                            | <b>285,887</b>                           | <b>262,678</b> | <b>126,957</b>                       | <b>113,436</b> |

The accompanying notes are an integral part of the financial statements.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

**Srivichaivejvitat Public Company Limited and its subsidiaries****Cash flow statements (continued)****For the six-month period ended 30 June 2026****DRAFT***This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

(Unit: Thousand Baht)

|                                                                | <b>Consolidated financial statements</b> |                  | <b>Separate financial statements</b> |                  |
|----------------------------------------------------------------|------------------------------------------|------------------|--------------------------------------|------------------|
|                                                                | <u>2026</u>                              | <u>2025</u>      | <u>2026</u>                          | <u>2025</u>      |
| <b>Cash flows from investing activities</b>                    |                                          |                  |                                      |                  |
| Increase in other current financial assets                     | (112,452)                                | (347,536)        | (112,091)                            | (100,000)        |
| Cash received from lease receivables                           | -                                        | -                | 432                                  | 432              |
| Decrease in restricted bank deposits                           | -                                        | 348              | -                                    | -                |
| Acquisition of buildings improvement and equipment             | (38,806)                                 | (67,481)         | (16,098)                             | (23,212)         |
| Cash paid for payable of buildings improvement and equipment   | (25,948)                                 | (25,545)         | (4,481)                              | (2,769)          |
| Acquisition of intangible assets                               | (468)                                    | (3,259)          | (268)                                | (2,478)          |
| Cash receipt from dividend of subsidiaries                     | -                                        | -                | 178,767                              | 363,656          |
| Cash receipt from dividend of related company                  | 2,835                                    | 4,050            | 2,835                                | 4,050            |
| Proceeds from sales of equipment                               | 162                                      | 63               | 24                                   | 250              |
| Advance for purchase of equipment                              | (540)                                    | (979)            | -                                    | -                |
| Cash paid for payable from purchase of investment              | -                                        | (6,161)          | -                                    | (6,161)          |
| Interest paid                                                  | -                                        | (339)            | -                                    | (339)            |
| Interest received                                              | 1,799                                    | 1,061            | 1,682                                | 154              |
| <b>Net cash from (used in) investing activities</b>            | <b>(173,418)</b>                         | <b>(445,778)</b> | <b>50,802</b>                        | <b>233,583</b>   |
| <b>Cash flows from financing activities</b>                    |                                          |                  |                                      |                  |
| Payment of principal portion of lease liabilities              | (5,056)                                  | (4,171)          | -                                    | (37)             |
| Treasury shares                                                | -                                        | (2,787)          | -                                    | (2,787)          |
| Advance received from share subscription                       | 68,656                                   | -                | 68,656                               | -                |
| Interest paid                                                  | (2,053)                                  | (2,046)          | -                                    | -                |
| Dividend paid                                                  | (246,510)                                | (151,814)        | (246,510)                            | (151,814)        |
| Dividend paid to non-controlling interests of the subsidiaries | (892)                                    | (1,618)          | -                                    | -                |
| <b>Net cash used in financing activities</b>                   | <b>(185,855)</b>                         | <b>(162,436)</b> | <b>(177,854)</b>                     | <b>(154,638)</b> |
| <b>Net increase (decrease) in cash and cash equivalents</b>    | <b>(73,386)</b>                          | <b>(345,536)</b> | <b>(95)</b>                          | <b>192,381</b>   |
| Cash and cash equivalents at beginning of period               | 807,291                                  | 1,041,910        | 227,553                              | 130,103          |
| <b>Cash and cash equivalents at end of period</b>              | <b>733,905</b>                           | <b>696,374</b>   | <b>227,458</b>                       | <b>322,484</b>   |

**Supplemental cash flows information**

Non-cash items consist of:

Acquisition of buildings improvement and equipment

|                                 |        |        |       |        |
|---------------------------------|--------|--------|-------|--------|
| for which no cash has been paid | 11,344 | 30,824 | 5,628 | 12,982 |
|---------------------------------|--------|--------|-------|--------|

Transfer of advances for purchase of fixed assets

|                                  |       |       |     |    |
|----------------------------------|-------|-------|-----|----|
| to property, plant and equipment | 1,292 | 2,762 | 525 | 70 |
|----------------------------------|-------|-------|-----|----|

Additions to right-of-use assets and lease liabilities

|  |       |       |   |   |
|--|-------|-------|---|---|
|  | 3,215 | 3,826 | - | - |
|--|-------|-------|---|---|

Transfer of right-of-use assets

|                                  |   |  |  |  |
|----------------------------------|---|--|--|--|
| to property, plant and equipment | - |  |  |  |
|----------------------------------|---|--|--|--|

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

The accompanying notes are an integral part of the financial statements.

**Srivichaivejvivat Public Company Limited and its subsidiaries**  
**Condensed notes to interim financial statements**  
**For the three-month and six-month periods ended 30 June 2026**

**DRAFT**

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

**1. General information**

**1.1 Basis for the preparation of interim financial statements**

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company presenting condensed interim financial statements. The Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements and has presented notes to the interim financial statements on a condensed basis.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

**1.2 Basis of consolidation**

The interim consolidated financial statements have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 December 2025, with no change in shareholding structure of the Company and its subsidiaries during the current period.

**1.3 Accounting policies**

The interim financial statements are prepared using the same accounting policies and methods of computation as those applied in the financial statements for the year ended 31 December 2025.

The revised financial reporting standards that became effective for annual reporting periods beginning on or after 1 January 2026 do not have any significant impact on the Company and its subsidiaries' financial statements.

In addition, the Federation of Accounting Professions has issued new and revised financial reporting standards which will become effective in the future. The standard involving changes to key principles is summarised below:

*We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.*

.....

**Directors**

**TFRS 18 Presentation and Disclosure in Financial Statements****DRAFT***This document is in draft form. It is subject to revision and the directors' consent cannot be relied upon as being definite.*

TFRS 18 will become effective for annual reporting periods beginning on or after 1 January 2028 and supersedes TAS 1, Presentation of Financial Statements. The standard introduces new requirements for classifying income and expenses into categories and presenting subtotals in the profit or loss. It also requires disclosures of management-defined performance measures and includes new requirements for the aggregation and disaggregation of financial information.

The management of the Company and its subsidiaries is currently evaluating the impact of this standard on the financial statements in the year of initial adoption.

**2. Related party transactions**

During the periods, the Company and its subsidiaries had significant business transactions with related parties. Such transactions, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and its subsidiaries and those related parties. There were no significant changes in the pricing policy of transactions with related parties.

Significant business transactions with related parties are summarised as follows.

(Unit: Million Baht)

|                                                         | For the three-month periods ended 30 June |             |                      |             |
|---------------------------------------------------------|-------------------------------------------|-------------|----------------------|-------------|
|                                                         | Consolidated                              |             | Separate             |             |
|                                                         | financial statements                      |             | financial statements |             |
|                                                         | <u>2026</u>                               | <u>2025</u> | <u>2026</u>          | <u>2025</u> |
| <u>Transactions with subsidiaries</u>                   |                                           |             |                      |             |
| (eliminated from the consolidated financial statements) |                                           |             |                      |             |
| Medical service income                                  | -                                         | -           | 2                    | 3           |
| Dividend income                                         | -                                         | -           | 179                  | 165         |
| Medical service expenses                                | -                                         | -           | 3                    | 3           |
| <u>Transaction with related company</u>                 |                                           |             |                      |             |
| Dividend income                                         | 3                                         | 4           | 3                    | 4           |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

(Unaudited but reviewed)

**DRAFT**

(Unit: Million Baht)

For the six-month periods ended 30 June

*This document is in draft form. It is subject to change and its contents cannot be relied upon as being accurate.*

|                                                         | Consolidated         |             | Separate             |             |
|---------------------------------------------------------|----------------------|-------------|----------------------|-------------|
|                                                         | financial statements |             | financial statements |             |
|                                                         | <u>2026</u>          | <u>2025</u> | <u>2026</u>          | <u>2025</u> |
| <u>Transactions with subsidiaries</u>                   |                      |             |                      |             |
| (eliminated from the consolidated financial statements) |                      |             |                      |             |
| Medical service income                                  | -                    | -           | 4                    | 6           |
| Dividend income                                         | -                    | -           | 179                  | 364         |
| Medical service expenses                                | -                    | -           | 7                    | 12          |
| <u>Transaction with related company</u>                 |                      |             |                      |             |
| Dividend income                                         | 3                    | 4           | 3                    | 4           |

The balances of the accounts between the Company, its subsidiaries and those related parties are as follows:

|                                                              | (Unit: Thousand Baht) |             |                      |              |
|--------------------------------------------------------------|-----------------------|-------------|----------------------|--------------|
|                                                              | Consolidated          |             | Separate             |              |
|                                                              | financial statements  |             | financial statements |              |
|                                                              | 30 June               | 31 December | 30 June              | 31 December  |
|                                                              | <u>2026</u>           | <u>2025</u> | <u>2026</u>          | <u>2025</u>  |
|                                                              |                       | (Audited)   |                      | (Audited)    |
| <u>Trade and other current receivables - related parties</u> |                       |             |                      |              |
| (Note 3)                                                     |                       |             |                      |              |
| Subsidiaries                                                 | -                     | -           | 2,421                | 3,024        |
| Related company                                              | <u>358</u>            | <u>359</u>  | <u>-</u>             | <u>-</u>     |
| Total trade and other current receivables                    |                       |             |                      |              |
| - related parties                                            | <u>358</u>            | <u>359</u>  | <u>2,421</u>         | <u>3,024</u> |
| <u>Trade and other current payables - related parties</u>    |                       |             |                      |              |
| Subsidiaries                                                 | -                     | -           | 6,709                | 7,879        |
| Related company and individuals                              | <u>49</u>             | <u>19</u>   | <u>-</u>             | <u>-</u>     |
| Total trade and other current payables                       |                       |             |                      |              |
| - related parties                                            | <u>49</u>             | <u>19</u>   | <u>6,709</u>         | <u>7,879</u> |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

(Unaudited but reviewed)

**DRAFT**

*This document is in draft form. It is subject to review and change and management's consent cannot be relied upon as being accurate.*

Directors and management's benefits

During the periods, the Company and its subsidiaries had employee benefit expenses payable to their directors and management as below.

(Unit: Thousand Baht)

|                              | For the three-month periods ended 30 June |              |                      |              |
|------------------------------|-------------------------------------------|--------------|----------------------|--------------|
|                              | Consolidated                              |              | Separate             |              |
|                              | financial statements                      |              | financial statements |              |
|                              | <u>2026</u>                               | <u>2025</u>  | <u>2026</u>          | <u>2025</u>  |
| Short-term employee benefits | 10,389                                    | 9,149        | 5,324                | 4,657        |
| Post-employment benefits     | 202                                       | 173          | 61                   | 37           |
| Total                        | <u>10,591</u>                             | <u>9,322</u> | <u>5,385</u>         | <u>4,694</u> |

(Unit: Thousand Baht)

|                              | For the six-month periods ended 30 June |               |                      |               |
|------------------------------|-----------------------------------------|---------------|----------------------|---------------|
|                              | Consolidated                            |               | Separate             |               |
|                              | financial statements                    |               | financial statements |               |
|                              | <u>2026</u>                             | <u>2025</u>   | <u>2026</u>          | <u>2025</u>   |
| Short-term employee benefits | 20,841                                  | 19,208        | 10,727               | 10,306        |
| Post-employment benefits     | 405                                     | 345           | 123                  | 73            |
| Total                        | <u>21,246</u>                           | <u>19,553</u> | <u>10,850</u>        | <u>10,379</u> |

**3. Trade and other current receivables**

(Unit: Thousand Baht)

|                                                | Consolidated         |             | Separate             |             |
|------------------------------------------------|----------------------|-------------|----------------------|-------------|
|                                                | financial statements |             | financial statements |             |
|                                                | 30 June              | 31 December | 30 June              | 31 December |
|                                                | <u>2026</u>          | <u>2025</u> | <u>2026</u>          | <u>2025</u> |
|                                                | (Audited)            |             | (Audited)            |             |
| <u>Trade receivables - related parties</u>     |                      |             |                      |             |
| Aged on the basis of due dates                 |                      |             |                      |             |
| Not yet due                                    | -                    | -           | 1,010                | 975         |
| Past due                                       |                      |             |                      |             |
| Up to 3 months                                 | -                    | -           | 191                  | 593         |
| 3 - 6 months                                   | -                    | -           | 323                  | 877         |
| 6 - 12 months                                  | -                    | -           | 744                  | 839         |
| Over 12 months                                 | -                    | -           | 671                  | 258         |
| Total                                          | -                    | -           | 2,939                | 3,542       |
| Less: Allowance for expected credit losses     | -                    | -           | (518)                | (518)       |
| Total trade receivables - related parties, net | -                    | -           | 2,421                | 3,024       |

*We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.*

Directors

(Unaudited but reviewed)

**DRAFT**

(Unit: Thousand Baht)

*This document is in draft form. It is subject to review and change and therefore its contents cannot be relied upon as being accurate.*

|                                                      | Consolidated<br>financial statements |                     | Separate<br>financial statements |                     |
|------------------------------------------------------|--------------------------------------|---------------------|----------------------------------|---------------------|
|                                                      | 30 June<br>2026                      | 31 December<br>2025 | 30 June<br>2026                  | 31 December<br>2025 |
|                                                      |                                      | (Audited)           |                                  | (Audited)           |
| <u>Trade receivables - unrelated parties</u>         |                                      |                     |                                  |                     |
| Aged on the basis of due dates                       |                                      |                     |                                  |                     |
| Not yet due                                          | 313,293                              | 312,500             | 84,732                           | 76,272              |
| Past due                                             |                                      |                     |                                  |                     |
| Up to 3 months                                       | 81,461                               | 88,055              | 14,688                           | 30,905              |
| 3 - 6 months                                         | 35,049                               | 21,260              | 3,547                            | 5,239               |
| 6 - 12 months                                        | 16,352                               | 8,233               | 3,809                            | 448                 |
| Over 12 months                                       | 5,257                                | 1,928               | 834                              | 642                 |
| Total                                                | 451,412                              | 431,976             | 107,610                          | 113,506             |
| Less: Allowance for expected credit losses           | (7,628)                              | (1,841)             | (826)                            | (642)               |
| Total trade receivables - unrelated parties, net     | 443,784                              | 430,135             | 106,784                          | 112,864             |
| Total trade receivables - net                        | 443,784                              | 430,135             | 109,205                          | 115,888             |
| <u>Other current receivables - related parties</u>   |                                      |                     |                                  |                     |
| Other current receivables                            | 358                                  | 359                 | -                                | -                   |
| Total other current receivables - related parties    | 358                                  | 359                 | -                                | -                   |
| <u>Other current receivables - unrelated parties</u> |                                      |                     |                                  |                     |
| Other current receivables                            | 5,760                                | 4,581               | 3,355                            | 3,351               |
| Accrued income                                       |                                      |                     |                                  |                     |
| Accrued social security income                       | 157,871                              | 140,543             | 111,226                          | 80,447              |
| Other accrued income                                 | 32,827                               | 64,480              | 6,754                            | 34,927              |
| Total                                                | 196,458                              | 209,604             | 121,335                          | 118,725             |
| Less: Allowance for expected credit losses           | (6,274)                              | (4,956)             | -                                | -                   |
| Total other current receivables                      |                                      |                     |                                  |                     |
| - unrelated parties, net                             | 190,184                              | 204,648             | 121,335                          | 118,725             |
| Total other current receivables - net                | 190,542                              | 205,007             | 121,335                          | 118,725             |
| Total trade and other current receivables - net      | 634,326                              | 635,142             | 230,540                          | 234,613             |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

**DRAFT**

*This document is in draft form. It is subject to revision and change without notice. Its contents cannot be relied upon as being accurate.*

#### 4. Warrants and share capital

On 30 December 2025, holders of the warrants to purchase ordinary shares of the Company No. 1 (VIH-W1) exercised 9,872,591 units to purchase 9,872,591 newly issued ordinary shares with a par value of Baht 1 each, at an exercise price of Baht 8 per share. The Company recorded a total of Baht 78,980,728 received from the exercise of rights as a separate item in the statement of financial position as at 31 December 2025 under the account “Advance received from share subscription”. The Company registered the increase in its issued and paid-up share capital with the Ministry of Commerce on 9 January 2026.

On 30 June 2026 (Final exercise date), holders of the warrants to purchase ordinary shares of the Company No. 1 (VIH-W1) exercised 8,582,012 units to purchase 8,582,012 newly issued ordinary shares with a par value of Baht 1 each, at an exercise price of Baht 8 per share. The Company recorded a total of Baht 68,656,096 received from the exercise of rights as a separate item in the statement of financial position as at 30 June 2026 under the account “Advance received from share subscription”. The Company registered the increase in its issued and paid-up share capital with the Ministry of Commerce on 6 July 2026.

In addition, the outstanding 503,198 warrants were expired on 30 June 2026.

#### 5. Treasury shares

On 28 February 2025, a meeting of the Company’s Board of Directors No.2/2025 passed a resolution approving the share repurchase program for financial management. The Company will repurchase its ordinary shares through the Stock Exchange of Thailand between 17 March 2025 to 16 September 2025 and will resell them after 3 months but not later than 3 years after the completion date of the share repurchase program.

As of the end of the repurchase period, the Company repurchased 404,700 million shares under the share repurchase program, equivalent to 0.07% of its issued and paid-up capital, at an average price of Baht 6.89 resulting in a total cost of Baht 2.79 million. At the same time, the Company has allocated retained earnings as a reserve for the same amount of treasury shares.

#### 6. Earnings per share

Basic earnings per share is calculated by dividing profit for the period attributable to equity holders of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issued during the period, net of treasury shares held by the Company.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors

(Unaudited but reviewed)

Diluted earnings per share is calculated by dividing profit for the period attributable to equity holder of the Company (excluding other comprehensive income) by the weighted average number of ordinary shares in issue during the period, net of treasury shares held by the Company plus the weighted average number of ordinary shares which would need to be issued to convert warrants into ordinary shares. The calculation assumes that the conversion took place either at the beginning of the period or on the date the potential ordinary shares were issued. However, the Company has not presented the diluted earnings per share for the three-month and six-month periods ended 30 June 2025 since the market price of ordinary share is lower than the exercise price of the warrants and has not presented the diluted earnings per share for the three-month and six-month periods ended 30 June 2026 since the warrants were expired on 30 June 2026 as described in Note 4.

The following table sets forth the computation of basic earnings per share:

|                                                                               | (Unit: Thousand Shares)                    |         |
|-------------------------------------------------------------------------------|--------------------------------------------|---------|
|                                                                               | Consolidated/Separate financial statements |         |
|                                                                               | For the three-month periods ended 30 June  |         |
|                                                                               | 2026                                       | 2025    |
| Number of ordinary shares issued and paid-up                                  | 608,774                                    | 608,709 |
| Number of newly issued ordinary shares as a result of the warrants' exercises | 9,873                                      | 65      |
| Effect of treasury share                                                      | (405)                                      | (252)   |
| Weighted average number of ordinary shares                                    | 618,242                                    | 608,522 |

|                                                                      | For the three-month periods ended 30 June |         |                               |         |
|----------------------------------------------------------------------|-------------------------------------------|---------|-------------------------------|---------|
|                                                                      | Consolidated financial statements         |         | Separate financial statements |         |
|                                                                      | 2026                                      | 2025    | 2026                          | 2025    |
| Profit attributable to equity holders of the Company (Thousand Baht) | 108,099                                   | 96,815  | 233,094                       | 209,318 |
| Weighted average number of ordinary shares (Thousand shares)         | 618,242                                   | 608,522 | 618,242                       | 608,522 |
| Basic earnings per share (Baht/share)                                | 0.1748                                    | 0.1591  | 0.3770                        | 0.3440  |

|                                                                               | (Unit: Thousand Shares)                    |         |
|-------------------------------------------------------------------------------|--------------------------------------------|---------|
|                                                                               | Consolidated/Separate financial statements |         |
|                                                                               | For the six-month periods ended 30 June    |         |
|                                                                               | 2026                                       | 2025    |
| Number of ordinary shares issued and paid-up                                  | 608,774                                    | 608,709 |
| Number of newly issued ordinary shares as a result of the warrants' exercises | 9,436                                      | 63      |
| Effect of treasury share                                                      | (405)                                      | (127)   |
| Weighted average number of ordinary shares                                    | 617,805                                    | 608,645 |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

Directors

(Unaudited but reviewed)

**DRAFT**

For the six-month periods ended 30 June

Consolidated financial statements Separate financial statements

|                                                                      | 2026    | 2025    | 2026    | 2025    |
|----------------------------------------------------------------------|---------|---------|---------|---------|
| Profit attributable to equity holders of the Company (Thousand Baht) | 207,247 | 195,401 | 269,458 | 454,095 |
| Weighted average number of ordinary shares (Thousand shares)         | 617,805 | 608,645 | 617,805 | 608,645 |
| Basic earnings per share (Baht/share)                                | 0.3355  | 0.3210  | 0.4362  | 0.7461  |

## 7. Segment information

The Company and its subsidiaries are principally engaged in the hospital business. A subsidiary is engaged in operating a vocational school, but the revenue from which is immaterial. The Company and its subsidiaries operate in a single geographic area in Thailand. Therefore, revenues, operating profit and total assets presented in the financial statements relate to the said principal business and location.

## 8. Dividends

Dividends declared during the six-month periods ended 30 June 2026 and 2025 consisted of the follows:

| Dividends                | Approved by                                                     | Total dividends<br>(Thousand Baht) | Dividend per share<br>(Baht) |
|--------------------------|-----------------------------------------------------------------|------------------------------------|------------------------------|
| Final dividends for 2024 | The Annual General Meeting of the shareholders on 21 April 2025 | 152,194                            | 0.25                         |
| Total for 2025           |                                                                 | 152,194                            | 0.25                         |
| Final dividends for 2025 | The Annual General Meeting of the shareholders on 24 April 2026 | 247,297                            | 0.40                         |
| Total for 2026           |                                                                 | 247,297                            | 0.40                         |

## 9. Commitments and contingent liabilities

### 9.1 Capital commitments

As at 30 June 2026 and 31 December 2025, the Company and its subsidiaries had capital commitments as follows:

|                                                         | (Unit: Million Baht)                 |                     |                                  |                     |
|---------------------------------------------------------|--------------------------------------|---------------------|----------------------------------|---------------------|
|                                                         | Consolidated<br>financial statements |                     | Separate<br>financial statements |                     |
|                                                         | 30 June<br>2026                      | 31 December<br>2025 | 30 June<br>2026                  | 31 December<br>2025 |
| Construction of buildings and the buildings improvement | 38.2                                 | 42.8                | 0.9                              | 6.9                 |
| Acquisition of medical devices and hospital equipment   | 11.0                                 | 13.0                | 1.9                              | 4.8                 |
| Others                                                  | 0.4                                  | 0.2                 | -                                | -                   |
|                                                         | <b>Directors</b>                     |                     |                                  | <b>8</b>            |

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

**DRAFT***This document is in draft form. It is subject to review and changes and therefore its content cannot be relied upon as being accurate.***9.2 Service commitments**

The Company and its subsidiaries have entered into consulting, security services provider, medical equipment maintenance service, and other service agreements with related individuals and unrelated parties.

As at 30 June 2026, future minimum payments required under those service contracts were contracting to Baht 25 million (31 December 2025: Baht 37 million) (the Company only: Baht 8 million, 31 December 2025: Baht 14 million).

**9.3 Guarantees**

There were outstanding bank guarantees issued by banks on behalf of the Company and its subsidiaries in respect of certain performance bonds as required in the normal course of business as follows:

|                                                   | Consolidated         |             | Separate             |             |
|---------------------------------------------------|----------------------|-------------|----------------------|-------------|
|                                                   | financial statements |             | financial statements |             |
|                                                   | 30 June              | 31 December | 30 June              | 31 December |
|                                                   | 2026                 | 2025        | 2026                 | 2025        |
|                                                   |                      | (Audited)   |                      | (Audited)   |
| Bank guarantees for the medical treatment         |                      |             |                      |             |
| service contracts with the Social Security Office | 23.3                 | 47.7        | 13.6                 | 27.1        |
| Bank guarantees for the medical treatment         |                      |             |                      |             |
| service contracts with the National Health        |                      |             |                      |             |
| Security Office                                   | 1.4                  | 1.4         | 0.2                  | 0.2         |
| Bank guarantees for electricity use               | 4.5                  | 4.4         | 1.8                  | 1.8         |
| Bank guarantees for service contracts             | 1.1                  | 4.5         | -                    | -           |
| Bank guarantees for bidding of health check-up    |                      |             |                      |             |
| service contracts                                 | 35.0                 | 16.7        | -                    | -           |

**10. Approval of interim financial statements**

These interim financial statements were authorised for issue by the Company's Board of Directors on 14 August 2026.

We, being responsible for the preparation of these financial statements and notes thereto, hereby approve their issue in final form.

.....  
Directors